Immune modulation raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-08-30 and is reviewed periodically as new material appears.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | ≈3,108 Da | Synthetic 28-residue peptide |
| Amino acid count | 28 | N-terminal serine carries an acetyl group |
| Appearance | White to off-white powder | Lyophilized solid |
| Water solubility | Freely soluble | Dissolves in aqueous buffer |
| Common synonyms | Thymalfasin; Tα1 | Thymalfasin is the international nonproprietary name |
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
== Sources == Bartusis, Mark C. (1997). The Late Byzantine Army: Arms and Society, 1204–1453. University of Pennsylvania Press. ISBN 0-8122-1620-2. Geanakoplos, Deno John (1959). Emperor Michael Palaeologus and the West, 1258–1282: A Study in Byzantine-Latin Relations. Cambridge, Massachusetts: Harvard University Press. Nicol, Donald M. (1993) [1972]. The Last Centuries of Byzantium, 1261–1453 (Second ed.). Cambridge: Cambridge University Press. ISBN 978-0-521-43991-6. Wolff, Robert Lee (1969) [1962]. "The Latin Empire of Constantinople, 1204–1261". In Setton, Kenneth M.; Wolff, Robert Lee; Hazard, Harry W. (eds.). A History of the Crusades, Volume II: The Later Crusades, 1189–1311. Vol. 2 (Second ed.). Madison, Milwaukee, and London: University of Wisconsin Press. pp. 186–233. ISBN 0-299-04844-6.
Vitamin A deficiency is common in developing countries but rarely seen in developed countries. Approximately 250,000 to 500,000 malnourished children in the developing world go blind each year from a deficiency of vitamin A. Vitamin A deficiency in expecting mothers increases the mortality rate of children shortly after childbirth. Night blindness is one of the first signs of vitamin A deficiency. Vitamin A deficiency contributes to blindness by depleting the necessary form needed for rhodopsin.
=== Necrotizing fasciitis === A study has found botox effective against necrotizing fasciitis caused by S. pyogenes in mice. Its mechanism of action is by blocking CGRP receptor of nerve cells, which trigger intense pain and activate CGRP cascade, which prevents the immune system attacks to control the pathogen. Botox blocks the CGRP cascade of nerve cells.
After graduating in 1953 from the University of Malaya, Mahathir began his housemanship at Penang General Hospital. In 1954, he was sent to Alor Setar General Hospital before being posted to government clinics in Langkawi, Jitra, and Perlis. During his time in Langkawi in 1955, Mahathir was the island's first stationed doctor, witnessing its underdeveloped state—a memory that later influenced his efforts to transform it into a major tourist destination when he became prime minister. Reflecting on his early career, Mahathir said he prioritised work over salary, starting with MYR 400.00 as a medical officer before a promotion raised it to MYR 770.00. He then resigned to open his private practice, named "Maha Klinik" (Maha Clinic), while his wife worked as a government doctor for 25 years. Maha Klinik was the first privately owned clinic established by a Malay in Malaysia. Mahathir acquired the reputation of being a caring doctor, willing to make house calls at any hour, trudging across rice fields in the dark to treat patients. If they could not afford his fee, they settled by installments or paid what they had. He was the town's first Malay physician and a successful one. He built a large house and employed a Chinese man to chauffeur him in his Pontiac Catalina (most chauffeurs at the time were Malay). Mahathir and Siti Hasmah were also involved in welfare and public health activities.
=== 1949–1950 === Crick taught himself the mathematical theory of X-ray crystallography. During the period of Crick's study of X-ray diffraction, researchers in the Cambridge lab were attempting to determine the most stable helical conformation of amino acid chains in proteins (the alpha helix). Linus Pauling was the first to identify the 3.6 amino acids per helix turn ratio of the alpha helix. Crick was witness to the kinds of errors that his co-workers made in their failed attempts to make a correct molecular model of the alpha helix; these turned out to be important lessons that could be applied, in the future, to the helical structure of DNA. For example, he learned the importance of the structural rigidity that double bonds confer on molecular structures which is relevant both to peptide bonds in proteins and the structure of nucleotides in DNA.
Sources: en.wikipedia.org
At the Game Developers Conference in March 2015, Valve and Taiwanese electronics company HTC unveiled SteamVR and the HTC Vive—a virtual reality platform and a virtual reality headset. The platform would be distinguished by its "Lighthouse" motion tracking system, where sensors on the headset and its included motion controllers read the position of two base station devices mounted in the play area. This would allow for "room-scale" VR experiences, where the player would not be required to remain in a stationary position in front of a camera and would be able to freely walk around the space. In November 2017, Microsoft added beta support for the SteamVR service for Windows Mixed Reality headsets. In June 2019, Valve released its own VR headset, known as the Valve Index, positioned as a higher-end device with wider field of view and higher refresh rate. They were accompanied by updated motion controllers, which are strapped against the user's palms and have sensors to detect input pressure and individual fingers. In November 2025, Valve announced the Steam Frame, a standalone VR headset.
The formed PCT then undergoes post-translational modifications, resulting in the production small peptides and mature CT by removal of the C-terminal glycine from the immature CT by peptidylglycine α-amidating monooxygenase (PAM). In a microbial infected individual, non-neuroendocrine tissue also secretes PCT by expression of CALC-1. A microbial infection induces a substantial increase in the expression of CALC-1, leading to the production of PCT in all differentiated cell types. The function of PCT synthesized in nonneuroendocrine tissue due to a microbial infection is currently unknown, but its detection aids in the differentiation of inflammatory processes.
Nederlandse Omroep Stichting (Dutch pronunciation: [ˈneːdərlɑntsə ˈʔɔmrup ˈstɪxtɪŋ]; NOS [ˌɛnoːˈɛs] or rarely [nɔs]; English: Dutch Broadcasting Foundation) is one of the broadcasting organisations making up the Dutch public broadcasting system. Funded by the Dutch government, it has a special statutory obligation to make news and sports programmes for the three Dutch public television channels and the public radio services. The foundation's remit derives from the Dutch Media Act 2008, which stipulates that NOS produce regular and frequent programming of a public service nature, including, notably, a full and impartial news service and coverage of parliamentary procedures and debates, as well as reporting on sporting and other national events. NOS also acts as a technical coordinator for the Dutch public broadcasting system as a whole. In the event of emergencies and/or the breaking of a major news story, it can assume control of the public networks to provide coordinated coverage of events in cooperation with the other members of the system. NOS has correspondents in multiple countries, including a permanent studio in Washington, D.C. Programmes produced by NOS include its daily television and radio bulletins, the NOS Journaal. Parliamentary reports are shown from a special studio in the Hague. It also supplies news programmes aimed at children (Jeugdjournaal), teens (NOS Stories), young adults (NOS op 3), and sports followers (NOS Langs de Lijn, NOS Studio Sport). Programmes are made available via television, radio, and online.
Staining is a technique used to enhance contrast in samples, generally at the microscopic level. Stains and dyes are frequently used in histology (microscopic study of biological tissues), in cytology (microscopic study of cells), and in the medical fields of histopathology, hematology, and cytopathology that focus on the study and diagnoses of diseases at the microscopic level. Stains may be used to define biological tissues (highlighting, for example, muscle fibers or connective tissue), cell populations (classifying different blood cells), or organelles within individual cells. In biochemistry, it involves adding a class-specific (DNA, proteins, lipids, carbohydrates) dye to a substrate to qualify or quantify the presence of a specific compound. Staining and fluorescent tagging can serve similar purposes. Biological staining is also used to mark cells in flow cytometry, and to flag proteins or nucleic acids in gel electrophoresis. Light microscopes are used for viewing stained samples at high magnification, typically using bright-field or epi-fluorescence illumination. Staining is not limited to only biological materials, since it can also be used to study the structure of other materials; for example, the lamellar structures of semi-crystalline polymers or the domain structures of block copolymers.
Sources: en.wikipedia.org
Norton & Company Marcus Brauchli (1983), former managing editor, The Wall Street Journal and executive editor of The Washington Post Michael Caruso (1983), former editor-in-chief of Smithsonian who coined the term "elevator pitch" Max Alexander (1987), senior editor of People Dave Kansas (1990), COO of American Public Media Group; former editor-in-chief of TheStreet.com Charles Ardai (1991), founder of Juno and Hard Case Crime Janice Min (1991), former editor of Us Weekly, co-president and chief creative officer of Guggenheim Partners, head of The Hollywood Reporter and Billboard Tim Griffin (1992), former editor-in-chief of Artforum, director and chief curator of The Kitchen Michael Schaffer (1995), editor of Washingtonian and former editor of Washington City Paper Franklin Foer (1996), editor, The New Republic Marco Roth (1996), co-founder and editor of n+1 Christopher Bollen (1998), journalist, essayist, and former editor-in-chief of Interview Magazine Eli Sanders (1999), associate editor of The Stranger and winner of the Pulitzer Prize for Feature Writing in 2012 Sam Dolnick (2002), assistant managing editor of The New York Times, member of the Ochs-Sulzberger family Yoni Appelbaum (2003), senior editor for politics, The Atlantic Matthew Continetti (2003), associate editor and writer, The Weekly Standard Will Welch (2003), editor-in-chief of GQ Bari Weiss (2007), editor at Tablet and The New York Times op-ed section Atossa Araxia Abrahamian (2008), journalist and senior editor of The Nation
=== Alternative treatments for wounds: leeches and maggots === Medical leeches were cleared as a medical device in 2004 after being an indispensable tool in the 19th century and even in use in the Middle Ages. This unique use of creatures is utilized in many surgeries today. Leeches have the ability to assist with compromised tissue with the components of their saliva. Their saliva contains a local anesthetic, thrombin inhibitor, antibiotic properties and a histamine-like vasodilator. These capabilities help in surgeries such as transplants, skin grafts, and even reconstructive surgeries. The leeches help localize the wound and help produce blood flow. This is helpful in operations where blood clots occur and they help dilate the blood vessels. Baron Dominique Jean Larrey, surgeon-in-chief of Napoleon's Grande Armée pioneered the use of maggots to prevent infection in wounds. They were also used by military medical aids during World War II. They worked as biomedical debriding agents by ingesting bacteria and breaking them down within their intestines. Maggots give off an enzyme that disinfects wounds and promotes healing and this is why they became the first organism in the United States that were used as a medical device in January 2004.
== Fleet replacement and lifecycle management == The timely replacement of vehicles and equipment is a process that requires the ability to predict asset lifecycles based on costing information, utilization, and asset age. Organizations prefer to use new fleet as a strategy for cost reduction where the used fleet is sold so that a new fleet is maintained. Funding requirements are also an issue, because many organizations, especially government, purchase vehicles with cash. The ad hoc nature and traditional low funding levels with cash has put many operations in an aged fleet. This lack of adequate funding for replacement can also result in higher maintenance costs due to aged vehicles.
Sources: en.wikipedia.org
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.
It is usually described as an immunomodulatory peptide rather than a classic hormone. It acts on immune cells through receptor pathways. No single endocrine organ target defines its function.
Several countries, including Italy and China, allow it for specific indications. The FDA has not approved it as a drug in the United States. Availability depends on local regulation.
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.